Aegle Therapeutics has raised $4 million to fund the first clinical trial evaluating AGLE-102, a therapy candidate for…
Articles by Ana Pena, PhD
The experimental cell therapy EB-101 was safe and led to successful wound healing in seven adults with recessive…
Cell therapy with genetically engineered skin grafts requires that collagen type VII be “corrected” in two types of skin cells…
Amryt Pharma is conducting a Phase 3 clinical trial evaluating the effectiveness and long-term safety of Oleogel-S10 (AP101),…
The U.S. Food and Drug Administration (FDA) has released a guidance document to assist and encourage industry in…
A skin-like device that measures heart rate, breathing, blood oxygen, blood pressure, and body temperature may provide a…
Gene therapy using CRISPR-Cas9 enabled precise correction in the lab of defective skin…
A new company called Wings Therapeutics has been tasked with continuing the development…
The collagen XVII mutation p.R1303Q that causes late-onset, mild junctional epidermolysis bullosa (JEB)Â is characterized by a…
A low dose of calcipotriol, which is already approved for the treatment of psoriasis, may improve healing…
RGN-137, an experimental therapy for wound healing in epidermolysis bullosa (EB)…
A case report shows that epidermolysis bullosa acquisita (EBA), a rare form of…